Report #2850775

Received Jul 23, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: IN
Recovered: Unknown
Vaccinated: Feb 1, 2023
Onset: Feb 1, 2025
Days to onset: 731
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	—	—

Symptoms (2)

Incomplete course of vaccinationNo adverse event

Symptom narrative

First Dose of HEPLISAV-B in February 2025 Has Not Received Next Dose; Initial report received on 07-Jul-2025. A pharmacist reported that a 58-year-old female received the first dose of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization in Feb-2023 and has not received another dose yet. No medical history or concomitant medications were reported. In Feb-2023, the patient received dose 1 of a hepatitis B vaccine HEPLISAV-B (lot number, expiration date, NDC number, route, and site not available). On 07-Jul-2025, approximately 2 years and 5 months after receiving the first dose HEPLISAV-B, the reporter contacted medical information to inquire if the HEPLISAV-B series needed to be restarted. No adverse reactions were reported. The reporter declined to provide further information. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.